Renibus Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $111M

  • Investors
  • 5

Renibus Therapeutics General Information

Description

Operator of a biotechnology company intended to develop novel pharmacologic therapies. The company develops novel therapeutics for post-operative surgery complications as well as acute and chronic kidney disease and offers advances for the prevention and management of such diseases, enabling the healthcare sector to access novel therapies to treat various types of health problems and transform outcomes in cardiothoracic surgical patients.

Contact Information

Website
www.renibus.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 181 Grand Avenue
  • Suite 225
  • Southlake, TX 76092
  • United States
+1 (682)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 181 Grand Avenue
  • Suite 225
  • Southlake, TX 76092
  • United States
+1 (682)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Renibus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B1) 17-Jul-2025 $111M Completed Clinical Trials - Phase 3
3. General Corporate Purpose 14-Nov-2022 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 17-Feb-2022 $34.6M $45.8M Completed Clinical Trials - Phase 2
1. Early Stage VC 02-May-2016 $11.2M $11.2M Completed Startup
To view Renibus Therapeutics’s complete valuation and funding history, request access »

Renibus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1
Series B
Series A 13,565,892 $0.001000 8% $2.58 $2.58 1x $2.58 18.2%
To view Renibus Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Renibus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop novel pharmacologic therapies. The company develops novel therap
Drug Discovery
Southlake, TX
29 As of 2026

Palo Alto, CA
 

Florham Park, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Renibus Therapeutics Competitors (6)

One of Renibus Therapeutics’s 6 competitors is Bitterroot Bio, a Venture Capital-Backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bitterroot Bio Venture Capital-Backed Palo Alto, CA
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
Protagonist Therapeutics Formerly VC-backed Newark, CA
Cadrenal Therapeutics Formerly Angel backed Ponte Vedra Beach, FL
Ardelyx Formerly VC-backed Waltham, MA
To view Renibus Therapeutics’s complete competitors history, request access »

Renibus Therapeutics Patents

Renibus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213609-A1 Pharmaceutical compositions for the treatment of salicylate toxicity Pending 04-Apr-2025
US-20260157962-A1 Compositions of stannic protoporfin for long term stability and container closure systems for storing stannic protoporfin Pending 09-Dec-2024
WO-2026128454-A1 Compositions of stannic protoporfin for long term stability and container closure systems for storing stannic protoporfin Pending 09-Dec-2024
WO-2025165353-A1 Novel stannic protoporfin compositions, methods of making, and uses thereof Pending 31-Jan-2024
US-20250242033-A1 Novel stannic protoporfin compositions, methods of making, and uses thereof Pending 07-Nov-2023 A61K33/26
To view Renibus Therapeutics’s complete patent history, request access »

Renibus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Renibus Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bios Partners Venture Capital Minority
Cathexis Ventures Corporate Venture Capital Minority
Green Park & Golf Ventures Venture Capital Minority
AG Collective Capital Venture Capital Minority
CKG Management Venture Capital Minority
To view Renibus Therapeutics’s complete investors history, request access »

Renibus Therapeutics Investments (1)

Renibus Therapeutics’s most recent deal was a Corporate Asset Purchase with Tricida (IP and Inventory Assets) for . The deal was made on 21-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tricida (IP and Inventory Assets) 21-Feb-2023 Corporate Asset Purchase Buildings and Property
To view Renibus Therapeutics’s complete investments history, request access »

Renibus Therapeutics FAQs

  • When was Renibus Therapeutics founded?

    Renibus Therapeutics was founded in 2015.

  • Where is Renibus Therapeutics headquartered?

    Renibus Therapeutics is headquartered in Southlake, TX.

  • What is the size of Renibus Therapeutics?

    Renibus Therapeutics has 29 total employees.

  • What industry is Renibus Therapeutics in?

    Renibus Therapeutics’s primary industry is Drug Discovery.

  • Is Renibus Therapeutics a private or public company?

    Renibus Therapeutics is a Private company.

  • What is the current valuation of Renibus Therapeutics?

    The current valuation of Renibus Therapeutics is .

  • What is Renibus Therapeutics’s current revenue?

    The current revenue for Renibus Therapeutics is .

  • How much funding has Renibus Therapeutics raised over time?

    Renibus Therapeutics has raised $187M.

  • Who are Renibus Therapeutics’s investors?

    Bios Partners, Cathexis Ventures, Green Park & Golf Ventures, AG Collective Capital, and CKG Management have invested in Renibus Therapeutics.

  • Who are Renibus Therapeutics’s competitors?

    Bitterroot Bio, Phathom Pharmaceuticals, Protagonist Therapeutics, Cadrenal Therapeutics, and Ardelyx are some of the 6 competitors of Renibus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process